PCSAライブシグナル | Getagraph.comで利益を最大化

買う 142149 min ago

@ $2.43

発行日: 13 2月 2024 @ 05:26

リターン: -19.75%

前回のシグナル: 2月 7 - 04:26

前回のシグナル: 売る

リターン: 0.00 %

Live Chart Being Loaded With Signals

Commentary (21 5月 2024 @ 22:30):

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States...

Stats
本日の出来高	1 811.00
平均出来高	1.48M
時価総額	5.57M
EPS	$0 ( 2024-05-20 )
次の収益日	( $-0.980 ) 2024-08-08
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.230
ATR14	$0.0120 (0.62%)

Insider Trading

Date	Person	Action	Amount	type
2024-01-01	Young David	Buy	1 675	Common Stock
2024-01-01	Young David	Sell	518	Common Stock
2024-01-01	Young David	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Sell	1 675	Restricted Stock Units
2024-01-01	Stanker James H	Buy	1 675	Common Stock

INSIDER POWER
80.51
Last 99 transactions
Buy: 3 005 145 \| Sell: 402 801

ボリューム相関

長: -0.13 (neutral)

短: -0.78 (moderate negative)

Signal:(44.919) Neutral

Processa Pharmaceuticals, 相関

10 最も正の相関
VTNR	0.928
UXIN	0.926
VRM	0.924
PLL	0.92
AXDX	0.912
RNAZ	0.91
CNSP	0.904
MHUA	0.897
IRBT	0.896
SNAX	0.893

10 最も負の相関
FFNW	-0.912
HQY	-0.886
ADTH	-0.881
SFBC	-0.875
FGFPP	-0.867
ISRG	-0.859
AGNCP	-0.854
FSEA	-0.849
PRAX	-0.847
SRPT	-0.845

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Processa Pharmaceuticals, 相関 - 通貨/商品

-0.48
( neutral )

0.00
( neutral )

0.57
( weak )

Processa Pharmaceuticals, 財務諸表

Annual	2023
収益:	$0
総利益:	$-222.00 (0.00 %)
EPS:	$-0.850

FY	2023
収益:	$0
総利益:	$-222.00 (0.00 %)
EPS:	$-0.850

FY	2022
収益:	$0
総利益:	$-27.53M (0.00 %)
EPS:	$-68.10

FY	2021
収益:	$0.00
総利益:	$0.00 (0.00 %)
EPS:	$-0.750

Financial Reports:

No articles found.

Processa Pharmaceuticals, Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Processa Pharmaceuticals,

Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosis lipoidica, a chronic disfiguring condition. The company is also developing PCS12852, a novel selective 5-hydroxytryptamine 4 (5-HT4) receptor agonist that is in Phase 2A clinical trials for the treatment of gastroparesis, chronic constipation, constipation-predominant irritable bowel syndrome, and functional dyspepsia; PCS3117, a cytosine analog, which is in Phase 2B clinical trials for the treatment of pancreatic and non-small cell lung cancer; and PCS6422, an oral, potent, selective, and irreversible inhibitor of dihydropyrimidine dehydrogenase that is in Phase 1B clinical trials for treating metastatic colorectal and breast cancer. In addition, it develops PCS11T, an analog of SN38 and irinotecan drug for the treatment of various cancers. The company was incorporated in 2011 and is based in Hanover, Maryland.